Header Logo

Connection

FERDINANDOS SKOULIDIS to Mutation

Back to Details
This is a "connection" page, showing publications FERDINANDOS SKOULIDIS has written about Mutation.
FERDINANDOS SKOULIDIS
Connection Strength
0.874
Mutation
  1. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov. 2018 07; 8(7):822-835.
    View in: PubMed
    Score: 0.150
  2. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015 Aug; 5(8):860-77.
    View in: PubMed
    Score: 0.122
  3. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024 Nov 01; 14(11):2183-2208.
    View in: PubMed
    Score: 0.059
  4. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.058
  5. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571.
    View in: PubMed
    Score: 0.053
  6. A STING operation to expose KRAS and STK11 co-mutated lung cancers. Cancer Cell. 2022 10 10; 40(10):1073-1076.
    View in: PubMed
    Score: 0.051
  7. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung Cancer. 2022 04; 166:270-278.
    View in: PubMed
    Score: 0.047
  8. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021 06 24; 384(25):2371-2381.
    View in: PubMed
    Score: 0.046
  9. Transcription Strikes Back: Clinical Utility of Lung Adenocarcinoma Subtypes. Clin Cancer Res. 2021 02 15; 27(4):913-915.
    View in: PubMed
    Score: 0.045
  10. Co-occurring genomic alterations in?non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019 09; 19(9):495-509.
    View in: PubMed
    Score: 0.041
  11. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. Clin Cancer Res. 2016 Dec 01; 22(23):5851-5863.
    View in: PubMed
    Score: 0.033
  12. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506.
    View in: PubMed
    Score: 0.014
  13. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing. Lung Cancer. 2023 10; 184:107293.
    View in: PubMed
    Score: 0.013
  14. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. 2023 07 10; 41(7):1363-1380.e7.
    View in: PubMed
    Score: 0.013
  15. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 07; 34(7):589-604.
    View in: PubMed
    Score: 0.013
  16. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet. 2023 03 04; 401(10378):733-746.
    View in: PubMed
    Score: 0.013
  17. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040.
    View in: PubMed
    Score: 0.013
  18. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol. 2022 07; 6:e2100547.
    View in: PubMed
    Score: 0.012
  19. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022 03; 17(3):399-410.
    View in: PubMed
    Score: 0.012
  20. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res. 2022 02; 20(2):280-292.
    View in: PubMed
    Score: 0.012
  21. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 09; 597(7878):732-737.
    View in: PubMed
    Score: 0.012
  22. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020 Jan 31; 20(1):83.
    View in: PubMed
    Score: 0.011
  23. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 07 01; 79(13):3251-3267.
    View in: PubMed
    Score: 0.010
  24. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 2016 Mar 01; 76(5):999-1008.
    View in: PubMed
    Score: 0.008
  25. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clin Cancer Res. 2016 Feb 01; 22(3):609-20.
    View in: PubMed
    Score: 0.008
  26. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol Cancer Ther. 2011 Apr; 10(4):670-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.